A population of over 1.2 billion people is one heck of a target market, especially when insulated by language. ChineseInvestors.com (OTCQB: CIIX) has leveraged this demographic to market a broad range of products, services and information specifically for the Chinese speaking population.
Marijuana use is currently illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers in that country.
CBD has long been considered to have a broad range of medical benefits. Now, two major studies released in the last four months have scientifically validated the medicinal efficacy of CBD.
At first blush, India Globalization Capital (NYSE: IGC) would seem a curiosity clothed in an enigma. Just how does a NYSE company move from a successful mining orientation to a pioneer in the development of multiple cannabinoid-based pharmaceutical therapies to treat pain and disease?
India Globalization Capital (NYSE MKT: IGC) formerly mined and converted low-grade iron ore to high-grade ore until prices plummeted. It was then that company management made the decision that to preserve shareholder value it must change course.
Although the marijuana industry is comprised of some incredible companies, investors must be selective and focus on the real players.
Investors have had their eyes on Algae Dynamics Corp. (OTCQB: ADYNF), which has partnered with various Canadian universities (including the University of Waterloo and Western University) for access to research and to boost its cannabis extraction expertise.
ChineseInvestors.com, Inc. (OTCQB: CIIX) attended the ‘Invest 2017’ exhibition in Stuttgart, Germany, on April 7-8, 2017, anticipating that the conference would be an opportunity for CIIX to introduce its hemp companies and products to German investors, but CIIX is not alone in seeing the growth opportunities for medical cannabis in that market.
With an annual growth rate of nearly 60 percent, CBD oil has become one of the fastest-growing market categories in the country. U.S.-based ChineseInvestors.com, Inc. (OTCQB: CIIX) is set to capitalize on this meteoric growth.
ChineseInvestors.com, Inc. (OTCQB: CIIX) is projected to reach revenues of $14.8 million by fiscal year 2020, according to a new research report by Consilium Global Research.
America is in an opioid epidemic. On an average day, 91 Americans will die from an opioid-related overdose. That’s according to the CDC, which also reports that the number of prescription opioids sold in the U.S. has nearly quadrupled since 1999 despite no overall change in the amount of pain reported.
Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies.
The fastest-growing industry with the most consistent growth rate in North America is legal marijuana. A recent Forbes article says that the market could grow 700% by 2020.
Its drug development pipeline consists of treatments for seizures, neuropathic pain, and eating disorders, but one gaining attention is an experimental cannabis-based drug for Alzheimer’s disease, IGC-AD1.
Not satisfied with a 100,000+ user base, a recognizable 18-year-old brand, and a target market in excess of two billion Chinese speaking people, ChineseInvestors.com recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based, therapeutic health products online store, http://www.ChineseCBDoil.com.
